Search Results
Your search for ,aLl matches 18308 pages
Showing 1751 - 1800Surveyed Oncologists’ Attitudes Toward Ethical Implications of AI in Cancer Care
Researchers surveyed oncologists for their perspectives on how artificial intelligence (AI) may be responsibly integrated into some aspects of cancer care as well as how to protect patients from the hidden biases of AI, according to a recent study published by Hantel et al in JAMA Network Open....
NAPRC-Accredited Hospitals vs Nonaccredited Hospitals: Proctectomy Outcomes
Hospitals accredited by the American College of Surgeons (ACS) National Accreditation Program for Rectal Cancer (NAPRC) may demonstrate lower mortality and complication rates in patients undergoing proctectomy compared with nonaccredited hospitals, according to a recent study published by Harbaugh...
Prolonged Use of Progestogens May Be Linked to Increased Risk of Brain Cancer
Prolonged use of selected progestogen agents may be associated with an increased risk of developing intracranial meningioma, according to a recent study published by Roland et al in the BMJ. Background Progestogens are similar to the natural hormone progesterone, which are widely used in menopausal ...
Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer
Investigators have assessed medical malpractice trends related to active surveillance as a treatment strategy across different types of cancers, according to a recent study published by Chang et al in the Annals of Surgery. Background Active surveillance is a less invasive approach that reserves...
Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Domenica Lorusso, MD, PhD, and colleagues, the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial has shown that the addition of pembrolizumab to chemoradiotherapy improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced...
Eligibility for and Prevalence of Lung Cancer Screening in the United States in 2022
In a study reported in a research letter in JAMA Network Open, Henderson et al identified prevalence of lung cancer screening in the United States in 2022 using U.S. Preventive Services Task Force (USPSTF) 2021 and 2013 recommendations for screening eligibility. The USPSTF 2013 guidelines...
Early Breast Cancer: Nurse-Led Follow-up Intervention and Quality of Life After Treatment
In a Danish single-institution phase III trial (MyHealth) reported in the Journal of Clinical Oncology, Saltbæk et al found that nurse-led individualized follow-up was associated with significantly better breast cancer–specific quality of life compared with usual care after completion of primary...
Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer
On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind...
IKZF1 Genetic Variant May Contribute to Disparities in Risk of ALL in Pediatric Hispanic and Latino Patients
A genetic variant located on the IKZF1 gene may be responsible for disparities in the risk of acute lymphoblastic leukemia (ALL) among Hispanic and Latino children, according to a recent study published by de Smith et al in Cell Genomics. The findings offer insights into the causes of the disease...
Stage III Colorectal Cancer: Association of Immunoscore With Disease-Free Survival
In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free survival in patients with stage III colorectal cancer treated with adjuvant mFOLFOX6 (modified fluorouracil, leucovorin, and...
Gut Microbiome Signatures May Help Unravel Disparities in Early-Onset Colorectal Cancer
The composition of the gut microbiome may reveal distinct signatures associated with race, ethnicity, and age of onset in patients with colorectal cancer, according to a recent study published by Hein et al in the Journal of Immunotherapy and Precision Oncology. The findings provide insights into...
Response to Primary Systemic Therapy Could Dictate Whether Extensive Lymph Node Removal Is Needed in Patients With Breast Cancer
Extensive removal of the lymph nodes may be safely avoided in patients with breast cancer that has metastasized to the axillary nodes if treatment is tailored to their response to therapies such as chemotherapy prior to surgery, according to new findings presented by van Hemert et al at the 2024...
A Clinical Trial for Bladder Cancer Gave Me Back My Life
About 8 years ago, I was just a few years into menopause when I noticed blood in my urine. It wasn’t accompanied by pain, frequent urination, or any other troubling symptoms, so initially I wasn’t too concerned. But when I started passing pieces of tissue, I became alarmed and made an appointment...
Integrative Approaches to Managing Symptoms of Anxiety and Depression in Adults With Cancer
Guest Editor’s Note: Psychological distress is highly prevalent in cancer populations throughout the disease trajectory. Integrative modalities are being increasingly used for managing the associated symptoms. In this article, Joke Bradt, PhD, MT-BC, summarizes the latest joint guideline published ...
Kathy Giusti’s Experience With Stem Cell Transplant for Multiple Myeloma
In Kathy Giusti’s empowering and deeply personal book Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical System (HarperCollins, 2024), she details the shock of being diagnosed with multiple myeloma, in 1996, at the age of 37. Told she had 3 years to live, the book recounts how Ms....
From Fatal to Fearless: How Patients Can Take Control of Their Disease and Fear Cancer Less
In 1996, at the age of 37, Kathy Giusti was diagnosed with the incurable blood cancer multiple myeloma and told she had about 3 years to live. In the mid-1990s, effective therapies for this second most common blood cancer were nearly nonexistent. Standard of care for myeloma consisted of oral...
Effect of Exercise on Symptom Burden and Quality of Life in Patients With Metastatic Breast Cancer
Taking part in an exercise program may improve pain, fatigue, and quality of life in patients with metastatic breast cancer, according to recent findings presented by Hiensch et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1). Background “Although there’s been quite a lot of...
Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy
Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, with T-cell malignancies...
Updated Immune Classifier May Accurately Identify Patients With Triple-Negative Breast Cancer Who Are Unlikely to Respond to Immunotherapy
A novel genetic test may predict how patients with triple-negative early-stage breast cancer will respond to immunotherapy, according to new findings presented by Wolf et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA). The research may help patients who are unlikely to...
ASCO Releases Resource-Stratified Guideline for the Treatment of Metastatic Breast Cancer
ASCO has released a new guideline on the treatment of patients with metastatic breast cancer in resource-constrained settings, where maximal setting–recommended treatments are not available.1 The guideline, designed for clinicians, policymakers, and patients, provides stratified recommendations...
W. Kimryn Rathmell, MD, PhD, Selected as 17th Director of the NCI
W. Kimryn Rathmell, MD, PhD, took the helm as the 17th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on December 18, 2023. A renowned kidney cancer expert and influential leader in cancer research and patient care, Dr. Rathmell was selected by...
Brachytherapy Boost May Decrease the Duration of Androgen-Deprivation Therapy for High-Risk Prostate Cancer
The optimal management of high-risk prostate cancer remains a topic of ongoing investigation. The quest for therapy that maximizes cancer control while minimizing toxicity is constant. Over the past decade, there has been mounting evidence that the addition of a brachytherapy boost to external-beam ...
CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities
Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...
Cancer Care Providers Urge President Biden to Make Health Care a State of the Union Priority
In a news release issued by ASCO earlier this month, the society reported that The Association for Clinical Oncology (ASCO) was calling on President Biden to continue to prioritize access to high-quality, equitable cancer care in his State of the Union address. Specifically, the cancer care...
Adjuvant Pembrolizumab: A New Option for High-Risk Muscle-Invasive Urothelial Cancer
Adjuvant use of the PD-1 inhibitor pembrolizumab achieved a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma vs observation after surgical resection, according to an interim analysis of the phase ...
Use of Combination Immunotherapy Before Lung Cancer Surgery
Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center,...
Mantle Cell Lymphoma: Front-Line Therapy
“The practice of medicine is an art, not a trade….” —Sir William Osler Mantle cell lymphoma (MCL) accounts for approximately 5% to 7% of all lymphomas; the median age of patients with MCL is between 60 and 70 years. This lymphoma is generally considered incurable. Median survival in retrospective...
Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer
Managing patients with lung cancer in the current era of an increasing array of systemic treatments has become a complex balancing act of trying to improve outcomes and survival from a cancer perspective while taking the necessary treatment and monitoring steps for cardioprotection. With few...
Avelumab Plus Axitinib in Mismatch Repair–Proficient Recurrent or Persistent Endometrial Cancer
The combination of avelumab and axitinib may be effective in patients with mismatch repair–proficient recurrent or persistent endometrial cancer, according to new findings presented by Lee et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. Background...
Liquid Biopsy May Help Predict Outcomes in Patients With Gastroesophageal Cancers Following Immunotherapy
Monitoring circulating tumor DNA (ctDNA) levels with liquid biopsies could help physicians accurately assess treatment responses and predict future prognoses in patients with operable esophageal or gastroesophageal junction cancer receiving an immunotherapy doublet, according to a recent study...
FDA Grants Accelerated Approval to Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the multitarget kinase inhibitor (Iclusig) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). PhALLCON Efficacy was evaluated in...
Lillian L. Siu, MD, FRCPC, FASCO, FAACR, Named 2024–2025 AACR President-Elect
The American Association for Cancer Research (AACR) announced that its members have elected Lillian L. Siu, MD, FRCPC, FASCO, FAACR, as the 2024–2025 President-Elect of the AACR. Professional and Research Background Dr. Siu currently serves as Professor of Medicine at the University of Toronto; as ...
Hormonal Therapy Plus SBRT for Advanced Prostate Cancer
Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer, according to a recent study published by Nikitas et al in...
Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer
Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair–proficient (pMMR) advanced or ...
Localized or Advanced Prostate Cancer: Short- or Longer-Term Relugolix Plus Radiotherapy
In an analysis reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that treatment with relugolix was associated with rapid achievement of sustained castration in patients with localized or advanced prostate cancer who were also receiving radiotherapy. Study Details The analysis...
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
The artificial intelligence (AI)-based chatbot ChatGPT version 3.4 may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented by Patel et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on...
SABR for Patients With Primary Kidney Cancer Not Undergoing Resection
In a phase II study (FASTRACK II) reported in The Lancet Oncology, Shankar Siva, MBBS, PhD, and colleagues found that stereotactic ablative body radiotherapy (SABR) was effective in patients with primary kidney cancer who did not undergo resection. Study Details Seventy patients were enrolled in...
Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL
On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...
Enfortumab Vedotin Plus Pembrolizumab Yields Benefit in Key Subgroups With Advanced Urothelial Cancer
The combination of the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab achieved favorable rates of progression-free survival, overall survival, and objective responses compared with chemotherapy among key subgroups of patients with previously...
Trends in Breast Cancer Diagnoses During the COVID-19 Pandemic
Investigators may have identified a decrease in newly diagnosed breast cancer cases during the first year of the COVID-19 pandemic, according to a recent study published by Fefferman et al in Cancer Medicine. The findings highlight that breast cancer was not immune to pandemic-related stressors and ...
SABR in Patients With Early NSCLC and Interstitial Lung Disease
In a study reported in JAMA Oncology, David A. Palma, MD, PhD, and colleagues found that stereotactic ablative radiotherapy (SABR) met criteria for efficacy and toxicity in patients with early non–small cell lung cancer (NSCLC) and interstitial lung disease (ILD). As stated by the investigators,...
From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research
Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...
Nab-sirolimus in Advanced Malignant Perivascular Epithelioid Cell Tumors: AMPECT Trial Final Analysis
As reported in the Journal of Clinical Oncology by Wagner et al, final analysis of the phase II AMPECT trial has shown a median duration of response of more than 3 years in patients with advanced malignant perivascular epithelioid cell tumors treated with nab-sirolimus. The primary analysis of the...
Novel Dual-Target CAR T-Cell Therapy for Recurrent Glioblastoma
Targeting two brain tumor–associated proteins with chimeric antigen receptor (CAR) T-cell therapy may reduce solid tumor growth in patients with recurrent glioblastoma, according to results from a phase I trial published by Bagley et al in Nature Medicine. The findings suggest that the new...
Immunotherapy Trials for Metastatic NSCLC: FDA Pooled Analysis
In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Bernardo Haddock Lobo Goulart, MD, and colleagues found that response rate and progression-free survival were only moderately correlated with overall survival in first-line immunotherapy trials for...
HPV-Associated Oropharyngeal Cancer: Intratreatment FDG-PET Response as a Biomarker for De-escalation of Radiotherapy
The use of imaging midtreatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may guide the use of deintensified chemoradiotherapy, according to a phase II study from the University of Michigan presented by Regan et al at the 2024 Multidisciplinary Head and Neck...
Patients With Biochemical Recurrence of Prostate Cancer: Ga-68–RM2 PET-MRI vs MRI Alone for Lesion Detection
In a single-center phase II/III imaging trial reported in The Lancet Oncology, Duan and colleagues found that gallium Ga-68–labeled RM2 (Ga-68–RM2) positron-emission tomography (PET)-magnetic resonance imaging (MRI) outperformed MRI alone in positive findings and number of lesions detected in...
Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL: New Efficacy Analysis
A new matching adjusted indirect comparison of the efficacy of zanubrutinib vs acalabrutinib in relapsed or refractory chronic lymphocytic leukemia (CLL) based on data from the phase III ALPINE and ASCEND trials was presented by Shadman et al at the 28th Annual International Congress on Hematologic ...
Worsening Metabolic Syndrome May Increase Cancer Risk
Investigators may have identified a heightened risk of various types of cancers among patients with persistent and worsening metabolic syndrome, according to a recent study published by Deng et al in Cancer. Background Metabolic syndrome encompasses conditions such as high blood pressure, elevated...
Higher BMI May Be Linked to Complications Following Autologous Breast Reconstruction
Patients with a higher body mass index (BMI) may have a greater risk of overall and specific complications following autologous breast reconstruction, according to a recent study published by Barnes et al in Plastic and Reconstructive Surgery. Background Autologous breast reconstruction—an...
